Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRDC002
- Development stage
- Phase 1
- Lead developer
- C Ray Therapeutics
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TRDC002 is a radiopharmaceutical PET tracer developed by C Ray Therapeutics for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions. It consists of a PSMA-targeting ligand labeled with the radioisotope Copper-64 (64Cu). PSMA is a cell surface protein that is significantly overexpressed in the majority of prostate cancer cells, particularly in metastatic and recurrent disease. The use of 64Cu, which has a half-life of approximately 12.7 hours, offers advantages over shorter-lived isotopes like Gallium-68, including the ability to perform delayed imaging for improved tumor-to-background ratios and the feasibility of centralized production and distribution to remote clinical sites.
- Other names
- Copper-64 TRDC002Copper64 TRDC002Copper 64 TRDC00264Cu-labeled PSMA tracer
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on TRDC002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRDC002.